Sarepta Therapeutics specializes in precision genetic medicines for rare neuromuscular diseases, with a flagship focus on Duchenne muscular dystrophy (DMD). It commercializes exon-skipping therapies that restore a truncated but functional dystrophin protein and has advanced gene therapy for DMD, notably ELEVIDYS. The company’s platform combines RNA-targeted phosphorodiamidate morpholino oligomers (PMOs) with AAV-based gene delivery. Its customers are largely patients and clinicians treating progressive muscle-wasting disorders with limited alternative treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 611.1 | — | 196.9 | 373.4% |
| Q3 2025 | 399.4 | — | -179.9 | -404.3% |
| Q4 2025 | 442.9 | — | -282.9 | -255.8% |
| Q1 2026 | 730.8 | — | 331 | — |
| Q2 2026 | 401.3 | -34.3% | -4.9 | -102.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Strategic Education, Inc. (STRA), Zymeworks Inc. (ZYME), Midera Food Processing, Inc. (MFP), Mineralys Therapeutics, Inc. (MLYS), Alvotech (ALVO), Establishment Labs Holdings Inc. (ESTA)